Have You Heard?

News and Updates from Child Neurology Foundation

Eisai Announces FDA Approval of FYCOMPA® (perampanel) Oral Suspension for Adjunctive Therapy in the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures

Posted on:

New Formulation Expands Treatment Options for Epilepsy Patients with POS and PGTC Seizures Woodcliff Lake, NJ, May 2, 2016 – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset seizures (POS) with…  Read More

CURE: NOW ACCEPTING 2017 Seminar Series Applications!

Posted on:

Host a 2017 CURE Seminar At Your Institution   CURE is now accepting applications for the 2017 Frontiers in Research Seminar Series! Approximately 10 seminars will be sponsored at different institutions each academic year with one goal: to present cutting-edge epilepsy research to a wide audience of researchers, young investigators, students,…  Read More

CURE Travel Awards

Posted on:

CURE is Proud to Sponsor the Gordon Research Seminar and Gordon Research Conference on Mechanisms of Epilepsy & Neuronal Synchronization GRS August 20-21, 2016 | GRC August 21-26, 2016 PGA Catalunya Business and Convention Centre: Girona, Spain This conference is particularly valuable for young investigators given its small size and the opportunity it presents…  Read More

Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

Posted on:

– Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients(1) – Seizures are the most common TSC-related neurological condition, yet about 60% of patients don’t attain seizure control with available anti-epileptic therapies(2) – Results presented at…  Read More

CURE 2016 Cycle 2 Funding Opportunities: Now Accepting Grant Applications

Posted on:

CURE is now accepting LOIs for second 2016 grant cycle. Innovator Award – $50,000 USD paid over 1 year Taking Flight Award – $100,000 USD paid over 1 year CURE Epilepsy Award – $250,000 USD paid over 2 years Key priority areas for the CURE Epilepsy Award include: 1) Basic mechanisms…  Read More

Rare Disease are Not so Rare in Neurology

Posted on:

  Rare diseases are not so rare in neurology, so Neurology Reviews presents the 2nd annual Rare Neurological Disease Special Report, which includes a compendium of news articles covering a wide range of rare neurologic diseases with a focus on the role of key members of the care team involved in…  Read More

Enroll Now! CURE’s Epilepsy Genetics Initiative

Posted on:

Our partners at CURE are proud to report that enrollment in the Epilepsy Genetics Initiative (EGI) database continues to grow, with 53 individual epilepsy patients and 174 total participants currently registered. By building a database of genetic information for researchers to analyze, CURE’s signature EGI program hopes to advance the science behind precision…  Read More

OPENING SOON CURE 2016 Cycle 2 Funding Opportunities

Posted on:

OPENING SOON CURE 2016 Cycle 2 Funding Opportunities CURE will soon be accepting LOIs for our second 2016 grant cycle. Innovator Award – $50,000 USD paid over 1 year Taking Flight Award – $100,000 USD paid over 1 year CURE Epilepsy Award – $250,000 USD paid over 2 years Key…  Read More

MENU